Literature DB >> 24018822

Diagnostic relevance of plasma DNA and DNA integrity for breast cancer.

Oliver J Stötzer1, Julia Lehner, Debora Fersching-Gierlich, Dorothea Nagel, Stefan Holdenrieder.   

Abstract

Levels of ALU 115, ALU 247, DNA integrity ([1, 2]) and of the tumour markers CA 15-3 and CEA were analysed in the blood of 152 patients. Plasma levels of ALU 115 and ALU 247 were significantly higher in patients with locally confined (LBC; N = 65), metastatic breast cancer (MBC; N = 47), and benign diseases (N = 12) than in healthy controls (p < 0.001 for all comparisons). DNA integrity, CEA, and CA 15-3 were significantly higher in MBC than in benign controls and LBC but could not identify LBCs. The best discrimination of LBC from healthy controls was achieved by ALU 115 and ALU 247 (AUC 95.4 and 95.5 %) and of MBC from all control groups by CA 15-3 and CEA (AUC 83.2 and 79.1 %). Plasma DNA is valuable for the detection of LBC, while established tumour markers are most informative in MBC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24018822     DOI: 10.1007/s13277-013-1158-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

1.  Densities, length proportions, and other distributional features of repetitive sequences in the human genome estimated from 430 megabases of genomic sequence.

Authors:  Z Gu; H Wang; A Nekrutenko; W H Li
Journal:  Gene       Date:  2000-12-23       Impact factor: 3.688

2.  Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer.

Authors:  Stefan Holdenrieder; Petra Stieber; Joachim von Pawel; Hannelore Raith; Dorothea Nagel; Knut Feldmann; Dietrich Seidel
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

3.  Plasma DNA as a prognostic marker for stroke patients with negative neuroimaging within the first 24 h of symptom onset.

Authors:  Nicole Y-L Lam; Timothy H Rainer; Lawrence K-S Wong; Wynnie Lam; Y-M Dennis Lo
Journal:  Resuscitation       Date:  2005-12-01       Impact factor: 5.262

4.  Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer.

Authors:  Raquel Catarino; Maria M Ferreira; Helena Rodrigues; Ana Coelho; Ana Nogal; Abreu Sousa; Rui Medeiros
Journal:  DNA Cell Biol       Date:  2008-08       Impact factor: 3.311

Review 5.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

6.  Nucleosomal DNA fragments in autoimmune diseases.

Authors:  Stefan Holdenrieder; Peter Eichhorn; Ulrich Beuers; Walter Samtleben; Ulf Schoenermarck; Reinhart Zachoval; Dorothea Nagel; Petra Stieber
Journal:  Ann N Y Acad Sci       Date:  2006-09       Impact factor: 5.691

7.  Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.

Authors:  Hsueh-Wei Chang; Shing M Lee; Steven N Goodman; Gad Singer; Sarah K R Cho; Lori J Sokoll; Fredrick J Montz; Richard Roden; Zhen Zhang; Daniel W Chan; Robert J Kurman; Ie-Ming Shih
Journal:  J Natl Cancer Inst       Date:  2002-11-20       Impact factor: 13.506

8.  Increased plasma DNA integrity in cancer patients.

Authors:  Brant G Wang; Han-Yao Huang; Yu-Chi Chen; Robert E Bristow; Keyanunoosh Kassauei; Chih-Chien Cheng; Richard Roden; Lori J Sokoll; Daniel W Chan; Ie-Ming Shih
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

Review 9.  Clinical use of circulating nucleosomes.

Authors:  Stefan Holdenrieder; Petra Stieber
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

10.  Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls.

Authors:  M B Giacona; G C Ruben; K A Iczkowski; T B Roos; D M Porter; G D Sorenson
Journal:  Pancreas       Date:  1998-07       Impact factor: 3.327

View more
  13 in total

Review 1.  Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?

Authors:  Navid Sobhani; Daniele Generali; Fabrizio Zanconati; Marina Bortul; Bruna Scaggiante
Journal:  World J Clin Oncol       Date:  2018-04-10

Review 2.  Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures.

Authors:  Olga Golubnitschaja; Manuel Debald; Kristina Yeghiazaryan; Walther Kuhn; Martin Pešta; Vincenzo Costigliola; Godfrey Grech
Journal:  Tumour Biol       Date:  2016-07-22

3.  Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer.

Authors:  Sobuhi Iqbal; Sreenivas Vishnubhatla; Vinod Raina; Surabhi Sharma; Ajay Gogia; Suryanarayana S V Deo; Sandeep Mathur; Nutan Kumar Shukla
Journal:  Springerplus       Date:  2015-06-17

4.  Efficacy of assessing circulating cell-free DNA using a simple fluorescence assay in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a prospective observational study.

Authors:  Kwonoh Park; Miyoung Woo; Jeong Eun Kim; Jin-Hee Ahn; Kyung Hae Jung; Jin Roh; Gyungyub Gong; Sung-Bae Kim
Journal:  Oncotarget       Date:  2017-12-21

5.  Quantitation of cell-free DNA in blood is a potential screening and diagnostic maker of breast cancer: a meta-analysis.

Authors:  Huadi Wang; Zhen Liu; Jiansheng Xie; Zhanggui Wang; Xiaoyun Zhou; Yong Fang; Hongming Pan; Weidong Han
Journal:  Oncotarget       Date:  2017-10-11

6.  Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.

Authors:  Ziqiang Lin; James Neiswender; Bin Fang; Xuelei Ma; Jing Zhang; Xiuying Hu
Journal:  Oncotarget       Date:  2017-04-18

7.  The value of the plasma circulating cell-free DNA concentration and integrity index as a clinical tool for prostate cancer diagnosis: a prospective case-control cohort study in an Iranian population.

Authors:  Maryam Khani; Jalil Hosseini; Reza Mirfakhraie; Mohsen Habibi; Eznollah Azargashb; Farkhondeh Pouresmaeili
Journal:  Cancer Manag Res       Date:  2019-05-16       Impact factor: 3.989

Review 8.  Towards Circulating-Tumor DNA-Based Precision Medicine.

Authors:  Ai Hironaka-Mitsuhashi; Anna Sanchez Calle; Takahiro Ochiya; Shin Takayama; Akihiko Suto
Journal:  J Clin Med       Date:  2019-09-02       Impact factor: 4.241

Review 9.  Circulating DNA as biomarker in breast cancer.

Authors:  Heidi Schwarzenbach; Klaus Pantel
Journal:  Breast Cancer Res       Date:  2015-10-09       Impact factor: 6.466

10.  Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III).

Authors:  Shilpa Thakur; Andrew Tobey; Brianna Daley; Sungyoung Auh; Mary Walter; Dhaval Patel; Naris Nilubol; Electron Kebebew; Aneeta Patel; Kirk Jensen; Vasyl Vasko; Joanna Klubo-Gwiezdzinska
Journal:  Front Oncol       Date:  2019-09-18       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.